company background image
HLUN

H. Lundbeck CPSE:HLUN A Stock Report

Last Price

kr.23.41

Market Cap

kr.24.1b

7D

-1.5%

1Y

n/a

Updated

04 Oct, 2022

Data

Company Financials +
HLUN A fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

HLUN A Stock Overview

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally.

H. Lundbeck Competitors

Price History & Performance

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Pricekr.23.41
52 Week Highkr.38.78
52 Week Lowkr.21.94
Beta0
1 Month Change-15.20%
3 Month Change-36.97%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-25.86%

Recent News & Updates

Jul 20
Getting In Cheap On H. Lundbeck A/S (CPH:HLUN A) Is Unlikely

Getting In Cheap On H. Lundbeck A/S (CPH:HLUN A) Is Unlikely

H. Lundbeck A/S' ( CPH:HLUN A ) price-to-earnings (or "P/E") ratio of 31.6x might make it look like a strong sell right...

Shareholder Returns

HLUN ADK PharmaceuticalsDK Market
7D-1.5%2.9%1.6%
1Yn/a-0.7%-9.5%

Return vs Industry: Insufficient data to determine how HLUN A performed against the Danish Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how HLUN A performed against the Danish Market.

Price Volatility

Is HLUN A's price volatile compared to industry and market?
HLUN A volatility
HLUN A Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement5.5%
10% most volatile stocks in DK Market10.4%
10% least volatile stocks in DK Market3.0%

Stable Share Price: HLUN A is less volatile than 75% of Danish stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: Insufficient data to determine HLUN A's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19155,437Deborah Dunsirehttps://www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products.

H. Lundbeck Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
HLUN A fundamental statistics
Market Capkr.24.08b
Earnings (TTM)kr.1.24b
Revenue (TTM)kr.16.91b

18.8x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HLUN A income statement (TTM)
Revenuekr.16.91b
Cost of Revenuekr.3.63b
Gross Profitkr.13.29b
Other Expenseskr.12.05b
Earningskr.1.24b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 09, 2022

Earnings per share (EPS)1.24
Gross Margin78.57%
Net Profit Margin7.31%
Debt/Equity Ratio30.2%

How did HLUN A perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is HLUN A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLUN A?

Other financial metrics that can be useful for relative valuation.

HLUN A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.7x
Enterprise Value/EBITDA7.3x
PEG Ratio0.7x

Price to Earnings Ratio vs Peers

How does HLUN A's PE Ratio compare to its peers?

HLUN A PE Ratio vs Peers
The above table shows the PE ratio for HLUN A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average54.5x
ALK B ALK-Abelló
87.6x34.0%kr.27.9b
NOVO B Novo Nordisk
35.2x13.5%kr.1.8t
CHEMM ChemoMetec
70.8x24.8%kr.11.3b
4581 Taisho Pharmaceutical Holdings
25x3.8%JP¥442.7b
HLUN A H. Lundbeck
18.8x28.1%kr.24.4b

Price-To-Earnings vs Peers: HLUN A is good value based on its Price-To-Earnings Ratio (18.8x) compared to the peer average (54.6x).


Price to Earnings Ratio vs Industry

How does HLUN A's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Earnings vs Industry: HLUN A is expensive based on its Price-To-Earnings Ratio (18.8x) compared to the European Pharmaceuticals industry average (18.1x)


Price to Earnings Ratio vs Fair Ratio

What is HLUN A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLUN A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HLUN A's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of HLUN A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLUN A (DKK23.43) is trading below our estimate of fair value (DKK142.46)

Significantly Below Fair Value: HLUN A is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is H. Lundbeck forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


28.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HLUN A's forecast earnings growth (28.1% per year) is above the savings rate (0.1%).

Earnings vs Market: HLUN A's earnings (28.1% per year) are forecast to grow faster than the Danish market (9.1% per year).

High Growth Earnings: HLUN A's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HLUN A's revenue (7.7% per year) is forecast to grow faster than the Danish market (6.8% per year).

High Growth Revenue: HLUN A's revenue (7.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HLUN A's Return on Equity is forecast to be low in 3 years time (15.6%).


Discover growth companies

Past Performance

How has H. Lundbeck performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-18.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: HLUN A has a large one-off loss of DKK424.0M impacting its June 30 2022 financial results.

Growing Profit Margin: HLUN A's current net profit margins (7.3%) are lower than last year (11.6%).


Past Earnings Growth Analysis

Earnings Trend: HLUN A's earnings have declined by 18.3% per year over the past 5 years.

Accelerating Growth: HLUN A's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HLUN A had negative earnings growth (-37.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.1%).


Return on Equity

High ROE: HLUN A's Return on Equity (6.3%) is considered low.


Discover strong past performing companies

Financial Health

How is H. Lundbeck's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: HLUN A's short term assets (DKK10.5B) exceed its short term liabilities (DKK8.5B).

Long Term Liabilities: HLUN A's short term assets (DKK10.5B) exceed its long term liabilities (DKK9.2B).


Debt to Equity History and Analysis

Debt Level: HLUN A's net debt to equity ratio (18.5%) is considered satisfactory.

Reducing Debt: HLUN A's debt to equity ratio has increased from 8.5% to 30.2% over the past 5 years.

Debt Coverage: HLUN A's debt is well covered by operating cash flow (39.1%).

Interest Coverage: HLUN A's interest payments on its debt are well covered by EBIT (8.3x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is H. Lundbeck current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

H. Lundbeck Dividend Yield vs Market
How does H. Lundbeck dividend yield compare to the market?
SegmentDividend Yield
Company (H. Lundbeck)n/a
Market Bottom 25% (DK)1.8%
Market Top 25% (DK)6.7%
Industry Average (Pharmaceuticals)2.9%
Analyst forecast in 3 Years (H. Lundbeck)n/a

Notable Dividend: Unable to evaluate HLUN A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HLUN A's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HLUN A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HLUN A's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HLUN A has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Deborah Dunsire (60 yo)

4.08yrs

Tenure

kr.56,600,000

Compensation

Dr. Deborah Dunsire, M.D. serves as Director at Syros Pharmaceuticals, Inc. since September 09, 2021. She serves as Chief Executive Officer and President at H. Lundbeck A/S since September 1, 2018 and serv...


CEO Compensation Analysis

Deborah Dunsire's Compensation vs H. Lundbeck Earnings
How has Deborah Dunsire's remuneration changed compared to H. Lundbeck's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

kr.1b

Mar 31 2022n/an/a

kr.1b

Dec 31 2021kr.57mkr.10m

kr.1b

Sep 30 2021n/an/a

kr.2b

Jun 30 2021n/an/a

kr.2b

Mar 31 2021n/an/a

kr.2b

Dec 31 2020kr.26mkr.10m

kr.2b

Sep 30 2020n/an/a

kr.904m

Jun 30 2020n/an/a

kr.1b

Mar 31 2020n/an/a

kr.2b

Dec 31 2019kr.21mkr.9m

kr.2b

Sep 30 2019n/an/a

kr.3b

Jun 30 2019n/an/a

kr.3b

Mar 31 2019n/an/a

kr.4b

Dec 31 2018kr.14mkr.3m

kr.4b

Compensation vs Market: Deborah's total compensation ($USD7.59M) is above average for companies of similar size in the Danish market ($USD2.37M).

Compensation vs Earnings: Deborah's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: HLUN A's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: HLUN A's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of HLUN A?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders21,0620.002%
Institutions48,351,5564.9%
General Public944,467,09295.1%

Dilution of Shares: HLUN A only recently listed within the past 12 months, with total shares outstanding growing by -0.07% in the past year..


Top Shareholders

Top 25 shareholders own 4.66% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
1.04%
The Vanguard Group, Inc.
10,289,612DKK240.9m2.54%no data
0.7%
BlackRock, Inc.
6,906,110DKK161.7m0.99%no data
0.41%
Skagen AS
4,036,630DKK94.5m0%0.21%
0.3%
Bankinter Luxembourg S.A., Asset Management Arm
2,963,575DKK69.4m0%1.79%
0.29%
Dimensional Fund Advisors LP
2,860,771DKK67.0m-6.59%no data
0.26%
Handelsbanken Asset Management
2,556,015DKK59.8m-36.67%0.02%
0.19%
Argenta Bank Luxembourg SA
1,909,677DKK44.7m0%0.18%
0.15%
Danske Capital AS
1,530,399DKK35.8m0%0.04%
0.15%
Ariel Investments, LLC
1,469,135DKK34.4m0%0.05%
0.13%
Argenta Bank- en Verzekeringsgroep nv, Asset Management Arm
1,339,920DKK31.4m0%0.32%
0.13%
T. Rowe Price Group, Inc.
1,334,402DKK31.2m-6.98%no data
0.13%
Nykredit Asset Management A/S
1,318,097DKK30.9m3.57%0.12%
0.13%
Bi Asset Management FondsmÆGlerselskab A/S
1,275,685DKK29.9m0%0.08%
0.12%
Marathon Asset Management Limited
1,183,584DKK27.7m28.57%0.02%
0.092%
Charles Schwab Investment Management, Inc.
917,660DKK21.5m5.6%no data
0.074%
BNY Mellon Asset Management
737,596DKK17.3m2.79%no data
0.057%
ID-Sparinvest, Filial af Sparinvest S.A., Luxembourg
568,452DKK13.3m-41.8%0.02%
0.05%
Niche Asset Management Limited
500,000DKK11.7m0%0.36%
0.049%
Brandes Investment Partners, LP
486,071DKK11.4m0%0.01%
0.041%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
404,390DKK9.5m-4.4%no data
0.035%
Causeway Capital Management LLC
348,509DKK8.2m0%0.01%
0.034%
Vident Investment Advisory, LLC
342,228DKK8.0m-20.25%0.03%
0.034%
WisdomTree Asset Management, Inc.
336,318DKK7.9m2195.69%0.01%
0.031%
IFP Investment Management SA
310,000DKK7.3m0%1.26%
0.03%
BZ Bank Aktiengesellschaft, Asset Management Arm
300,000DKK7.0m0%0.67%

Company Information

H. Lundbeck A/S's employee growth, exchange listings and data sources


Key Information

  • Name: H. Lundbeck A/S
  • Ticker: HLUN A
  • Exchange: CPSE
  • Founded: 1915
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr.24.078b
  • Shares outstanding: 992.84m
  • Website: https://www.lundbeck.com

Number of Employees


Location

  • H. Lundbeck A/S
  • Ottiliavej 9
  • Valby
  • Capital Region of Denmark
  • 2500
  • Denmark


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HLUN ACPSE (OMX Nordic Exchange Copenhagen)YesA SharesDKDKKJun 2022
HLUN BCPSE (OMX Nordic Exchange Copenhagen)B SharesDKDKKJun 2022
HLUNACBATS-CHIXE (BATS 'Chi-X Europe')YesA SharesGBDKKJun 2022
LDBBDB (Deutsche Boerse AG)YesA SharesDEEURJun 2022
LDBADB (Deutsche Boerse AG)B SharesDEEURJun 2022
HLUNBCBATS-CHIXE (BATS 'Chi-X Europe')B SharesGBDKKJun 2022
HLUB.FOTCPK (Pink Sheets LLC)YesA SharesUSUSDJun 2022
HLBB.FOTCPK (Pink Sheets LLC)B SharesUSUSDJun 2022

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/04 00:00
End of Day Share Price2022/10/04 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.